Search research articles
Contact Us
Filters
Showing results (171-180 of 218) with videos related to
Page
of 22
Sort By:
Transplantation and Cellular Therapy
|
July 6, 2026
A Simplified Frailty Score Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation
Chelby Wakefield, Curtis Marcoux, Denái R Milton, et al.
Cancer
|
May 21, 2016
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma
Yago Nieto, Benigno C Valdez, Peter F Thall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 20, 2011
The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: a health care resource and infrastructure assessment
Navneet S Majhail, Elizabeth A Murphy, Ellen M Denzen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 5, 2018
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma
Yago Nieto, Peter F Thall, Junsheng Ma, et al.
Bone Marrow Transplantation
|
April 14, 2015
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation
Marina Konopleva, Christopher B Benton, Peter F Thall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 31, 2012
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies
Yago Nieto, Peter Thall, Ben Valdez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 23, 2013
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma
Qaiser Bashir, Hassan Khan, Peter F Thall, et al.
British Journal of Haematology
|
March 16, 2017
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma
Nina Shah, Li Li, Jessica McCarty, et al.
British Journal of Haematology
|
March 6, 2024
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation
Kamal Alzahrani, Oren Pasvolsky, Zhongya Wang, et al.
American Journal of Hematology
|
February 24, 2024
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial
Issa F Khouri, Kamal Alzahrani, Hagop Kantarjian, et al.
Page
of 22
Search research articles
Search
Showing results (171-180 of 218) with videos related to
Sort By:
Page
of 22
Transplantation and Cellular Therapy
|
July 6, 2026
A Simplified Frailty Score Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation
Chelby Wakefield, Curtis Marcoux, Denái R Milton, et al.
Cancer
|
May 21, 2016
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma
Yago Nieto, Benigno C Valdez, Peter F Thall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 20, 2011
The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: a health care resource and infrastructure assessment
Navneet S Majhail, Elizabeth A Murphy, Ellen M Denzen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 5, 2018
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma
Yago Nieto, Peter F Thall, Junsheng Ma, et al.
Bone Marrow Transplantation
|
April 14, 2015
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation
Marina Konopleva, Christopher B Benton, Peter F Thall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 31, 2012
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies
Yago Nieto, Peter Thall, Ben Valdez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 23, 2013
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma
Qaiser Bashir, Hassan Khan, Peter F Thall, et al.
British Journal of Haematology
|
March 16, 2017
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma
Nina Shah, Li Li, Jessica McCarty, et al.
British Journal of Haematology
|
March 6, 2024
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation
Kamal Alzahrani, Oren Pasvolsky, Zhongya Wang, et al.
American Journal of Hematology
|
February 24, 2024
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial
Issa F Khouri, Kamal Alzahrani, Hagop Kantarjian, et al.
Page
of 22